1903 related articles for article (PubMed ID: 8311008)
21. Phase II study of vindesine and dacarbazine with or without non-specific stimulation of the immune system in patients with metastatic melanoma.
Verschraegen CF; Legha SS; Hersh EM; Plager C; Papadopoulos N; Burgess MA
Eur J Cancer; 1993; 29A(5):708-11. PubMed ID: 8471328
[TBL] [Abstract][Full Text] [Related]
22. [Adjuvant chemotherapy as a component of complex treatment for skin melanoma].
Kudriavtsev DV; Kudriavtseva GT; Mardynskiĭ IuS
Vopr Onkol; 2008; 54(2):170-7. PubMed ID: 18522165
[TBL] [Abstract][Full Text] [Related]
23. Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
Saba HI; Cruse CW; Wells KE; Klein CJ; Reintgen DS
Ann Plast Surg; 1992 Jan; 28(1):65-9. PubMed ID: 1642409
[TBL] [Abstract][Full Text] [Related]
24. Combination chemotherapy with dacarbazine and vindesine in the treatment of metastatic malignant melanoma.
Vorobiof DA; Sarli R; Falkson G
Cancer Treat Rep; 1986 Jul; 70(7):927-8. PubMed ID: 3719588
[No Abstract] [Full Text] [Related]
25. Pilot study of preoperative chemotherapy with cisplatin, vinblastine, and dacarbazine in patients with local-regional recurrence of melanoma.
Buzaid A; Legha SS; Balch CM; Ross M; Ring S; Plager C; Papadopoulos NE; el-Naggar AK; Benjamin RS
Cancer; 1994 Nov; 74(9):2476-82. PubMed ID: 7923003
[TBL] [Abstract][Full Text] [Related]
26. Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.
Lian B; Si L; Cui C; Chi Z; Sheng X; Mao L; Li S; Kong Y; Tang B; Guo J
Clin Cancer Res; 2013 Aug; 19(16):4488-98. PubMed ID: 23833309
[TBL] [Abstract][Full Text] [Related]
27. A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma.
Steffens TA; Bajorin DF; Chapman PB; Lovett DR; Cody-Johnson BV; Templeton MA; Heelan RT; Wong GY; Portlock CS; Oettgen HF
Cancer; 1991 Sep; 68(6):1230-7. PubMed ID: 1873774
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant therapy of malignant melanoma: is there a choice?
Retsas S
Crit Rev Oncol Hematol; 2001 Nov; 40(2):187-93. PubMed ID: 11682325
[TBL] [Abstract][Full Text] [Related]
29. Dacarbazine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma: a phase II study.
Gundersen S
Cancer Treat Rep; 1987 Nov; 71(11):997-9. PubMed ID: 3677119
[No Abstract] [Full Text] [Related]
30. Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma.
Guida M; Latorre A; Mastria A; De Lena M
Eur J Cancer; 1996 Apr; 32A(4):730-3. PubMed ID: 8695281
[TBL] [Abstract][Full Text] [Related]
31. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Chapman PB; Einhorn LH; Meyers ML; Saxman S; Destro AN; Panageas KS; Begg CB; Agarwala SS; Schuchter LM; Ernstoff MS; Houghton AN; Kirkwood JM
J Clin Oncol; 1999 Sep; 17(9):2745-51. PubMed ID: 10561349
[TBL] [Abstract][Full Text] [Related]
32. Treatment of metastatic malignant melanoma with 24 hours continuous venous infusion of dacarbazine and cisplatin.
Icli F; Karaoguz H; Dincol D; Gunel N; Demirkazik A
J Surg Oncol; 1991 Nov; 48(3):199-201. PubMed ID: 1943117
[TBL] [Abstract][Full Text] [Related]
33. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
Rusthoven JJ; Quirt IC; Iscoe NA; McCulloch PB; James KW; Lohmann RC; Jensen J; Burdette-Radoux S; Bodurtha AJ; Silver HK; Verma S; Armitage GR; Zee B; Bennett K
J Clin Oncol; 1996 Jul; 14(7):2083-90. PubMed ID: 8683240
[TBL] [Abstract][Full Text] [Related]
34. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
Lewis KD; Robinson WA; McCarter M; Pearlman N; O'Day SJ; Anderson C; Amatruda TT; Baron A; Zeng C; Becker M; Dollarhide S; Matijevich K; Gonzalez R
J Clin Oncol; 2006 Jul; 24(19):3157-63. PubMed ID: 16809738
[TBL] [Abstract][Full Text] [Related]
35. Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit?
Hofmann MA; Sterry W; Trefzer U
Jpn J Clin Oncol; 2007 Mar; 37(3):224-9. PubMed ID: 17472972
[TBL] [Abstract][Full Text] [Related]
36. Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma.
Brennecke S; Deichmann M; Naeher H; Kurzen H
Melanoma Res; 2005 Dec; 15(6):515-22. PubMed ID: 16314737
[TBL] [Abstract][Full Text] [Related]
37. High-dose cisplatin plus dacarbazine in the treatment of metastatic melanoma.
Murren JR; DeRosa W; Durivage HJ; Davis C; Makuch R; Portlock CS
Cancer; 1991 Mar; 67(6):1514-7. PubMed ID: 2001539
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma.
Gibbs P; Iannucci A; Becker M; Allen J; O'Driscoll M; McDowell K; Williams P; Rosse P; Murphy J; Gonzalez R
Melanoma Res; 2000 Apr; 10(2):171-9. PubMed ID: 10803718
[TBL] [Abstract][Full Text] [Related]
39. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.
Scagliotti GV; Fossati R; Torri V; Crinò L; Giaccone G; Silvano G; Martelli M; Clerici M; Cognetti F; Tonato M;
J Natl Cancer Inst; 2003 Oct; 95(19):1453-61. PubMed ID: 14519751
[TBL] [Abstract][Full Text] [Related]
40. Cutaneous malignant melanoma in children.
Vandeweyer E; Sales F; Deraemaecker R
Eur J Pediatr; 2000 Aug; 159(8):582-4. PubMed ID: 10968235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
